Gene therapy to improve migration of T cells to the tumor site.
One requirement for anti-tumor T cells to be effective is their successful traffic to tumor sites. Trafficking of T cells to lymphoid organs and peripheral tissues is a multistage process. Soluble and tissue-bonded chemokines interacting with chemokine receptors expressed by T lymphocytes certainly play a pivotal role in determining migration under physiologic conditions and during inflammation. Therefore a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express is required. Since chemokine produced by the targeted tumor may not match the subset of chemokine receptors expressed by T cells, gene therapy can be used to force the expression of the specific chemokine receptor by effector T cells so that the anti-tumor activity of adoptively transferred anti-tumor T cells is maximized.
Di Stasi
Antonio
A
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
De Angelis
Biagio
B
Savoldo
Barbara
B
D000818:Animals; D001681:Biological Assay; D002465:Cell Movement; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000166:cytology* / Q000276:immunology; D014161:Transduction, Genetic